Brian D. Ross
YOU?
Author Swipe
View article: Momelotinib inhibition of JAK/STAT in a mouse JAKV617F myelofibrosis model showed concurrent activation of p-ERK and p-AKT which was reversed by combination therapy using LP-182, a novel MEK/PI3K/mTOR inhibitor
Momelotinib inhibition of JAK/STAT in a mouse JAKV617F myelofibrosis model showed concurrent activation of p-ERK and p-AKT which was reversed by combination therapy using LP-182, a novel MEK/PI3K/mTOR inhibitor Open
Introduction: Most cases of myelofibrosis (MF) arise from constitutive activation of the JAK/STAT signaling pathway in hematopoietic stem cells (HSCs) with resultant activation of bone marrow stromal cells driving fibrosis. Treatment optio…
View article: Quantitative MRI Assessment of Bone Marrow Disease in Myelofibrosis: A Prospective Study
Quantitative MRI Assessment of Bone Marrow Disease in Myelofibrosis: A Prospective Study Open
MRI helped quantify macromolecular and cellular changes in the bone marrow of individuals with myelofibrosis, with increased apparent diffusion coefficient values correlating with biopsy-proven fibrosis.
View article: Murine Functional Lung Imaging Using X-Ray Velocimetry for Longitudinal Noninvasive Quantitative Spatial Assessment of Pulmonary Airflow
Murine Functional Lung Imaging Using X-Ray Velocimetry for Longitudinal Noninvasive Quantitative Spatial Assessment of Pulmonary Airflow Open
Background/Objectives: The recent development of four-dimensional X-ray velocimetry (4DXV) technology (three-dimensional space and time) provides a unique opportunity to obtain preclinical quantitative functional lung images. Only single-s…
View article: Sirtuin 1 Activation Mitigates Murine Vasculitis Severity by Promoting Autophagy and Mitophagy
Sirtuin 1 Activation Mitigates Murine Vasculitis Severity by Promoting Autophagy and Mitophagy Open
BACKGROUND Sirtuin 1 (SIRT1), a NAD + -dependent protein deacetylase, regulates cardiovascular inflammation by modulating cellular stress, inhibiting NLRP3 activation, and promoting the clearance of damaged mitochondria. However, its preci…
View article: Fat Fraction MRI for Longitudinal Assessment of Bone Marrow Heterogeneity in a Mouse Model of Myelofibrosis
Fat Fraction MRI for Longitudinal Assessment of Bone Marrow Heterogeneity in a Mouse Model of Myelofibrosis Open
Background/Objectives: Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by the replacement of healthy bone marrow (BM) with malignant and fibrotic tissue. In a healthy state, bone marrow is composed of approximately 60–70%…
View article: A deep learning aided bone marrow segmentation of quantitative fat MRI for myelofibrosis patients
A deep learning aided bone marrow segmentation of quantitative fat MRI for myelofibrosis patients Open
Purpose To automate bone marrow segmentation within pelvic bones in quantitative fat MRI of myelofibrosis (MF) patients using deep-learning (DL) U-Net models. Methods Automated segmentation of bone marrow (BM) was evaluated for four U-Net …
View article: Synthesis and Biological Evaluation of MEK/mTOR Multifunctional Inhibitors as Novel Anticancer Agents
Synthesis and Biological Evaluation of MEK/mTOR Multifunctional Inhibitors as Novel Anticancer Agents Open
The mitogen-activated protein kinase (MAPK) and mechanistic target of rapamycin (mTOR) signaling nodes play a crucial role in many human cancers. Due to the molecular reciprocity between MAPK and mTOR signaling nodes, development of compou…
View article: Quantitative <scp>MRI</scp> reveals heterogeneous impacts of treatment on diseased bone marrow in a mouse model of myelofibrosis
Quantitative <span>MRI</span> reveals heterogeneous impacts of treatment on diseased bone marrow in a mouse model of myelofibrosis Open
Purpose Analyzing bone marrow in the hematologic cancer myelofibrosis requires endpoint histology in mouse models and bone marrow biopsies in patients. These methods hinder the ability to monitor therapy over time. Preclinical studies typi…
View article: Co-Clinical Imaging Metadata Information (CIMI) for Cancer Research to Promote Open Science, Standardization, and Reproducibility in Preclinical Imaging
Co-Clinical Imaging Metadata Information (CIMI) for Cancer Research to Promote Open Science, Standardization, and Reproducibility in Preclinical Imaging Open
Preclinical imaging is a critical component in translational research with significant complexities in workflow and site differences in deployment. Importantly, the National Cancer Institute’s (NCI) precision medicine initiative emphasizes…
View article: Figure S1 from A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis
Figure S1 from A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis Open
Supplemental Figure 1
View article: Supplementary Figure 2 from Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer
Supplementary Figure 2 from Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer Open
PDF file, 41KB, Changes in weight during the study period for the mice randomized to the eight treatment groups described.
View article: Supplementary Figure Legend from Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer
Supplementary Figure Legend from Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer Open
PDF file, 44KB.
View article: Supplementary Figure 4 from Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer
Supplementary Figure 4 from Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer Open
PDF file, 332KB, Immunoblotting for cleaved PARP 24 hours after radiation treatment, PD0325901, and API-2 treatment to detect activation of apoptotic pathways.
View article: Data from A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis
Data from A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis Open
Responses to targeted therapies frequently are brief, with patients relapsing with drug-resistant tumors. For oncogenic MEK and BRAF inhibition, drug resistance commonly occurs through activation of PI3K/AKT/mTOR signaling and immune check…
View article: Supplementary Figure 1 from Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer
Supplementary Figure 1 from Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer Open
PDF file, 318KB, Dose dependency of PD0325901 in multiple cell lines. Treatment with PD0325901 induces potent inhibition of pERK-1/2 levels at one and three hours.
View article: Data from Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer
Data from Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer Open
There is an urgent need for the development of novel therapies to treat pancreatic cancer, which is among the most lethal of all cancers. KRAS-activating mutations, which are found in more than 90% of pancreatic adenocarcinomas, drive tumo…
View article: Supplementary Figure 4 from Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer
Supplementary Figure 4 from Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer Open
PDF file, 332KB, Immunoblotting for cleaved PARP 24 hours after radiation treatment, PD0325901, and API-2 treatment to detect activation of apoptotic pathways.
View article: Supplemental Data from A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis
Supplemental Data from A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis Open
Figure Legends
View article: Supplementary Figure 1 from Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer
Supplementary Figure 1 from Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer Open
PDF file, 318KB, Dose dependency of PD0325901 in multiple cell lines. Treatment with PD0325901 induces potent inhibition of pERK-1/2 levels at one and three hours.
View article: Supplementary Figure 3 from Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer
Supplementary Figure 3 from Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer Open
PDF file, 327KB, Treatment of MIA-PaCa-2 cells with API-2 induces potent inhibition of Akt activation at 1 hour, regardless of the presence of PD0325901.
View article: Data from Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer
Data from Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer Open
There is an urgent need for the development of novel therapies to treat pancreatic cancer, which is among the most lethal of all cancers. KRAS-activating mutations, which are found in more than 90% of pancreatic adenocarcinomas, drive tumo…
View article: Figure S2 from A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis
Figure S2 from A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis Open
Supplemental Figure 2
View article: Supplementary Figure 5 from Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer
Supplementary Figure 5 from Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer Open
PDF file, 48KB, Changes in MRI tumor volume for mice treated with radiation alone, API-2, or radiation with API-2. There was no radiosensitization observed with API-2 in the absence of a MEK inhibitor.
View article: Figure S2 from A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis
Figure S2 from A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis Open
Supplemental Figure 2
View article: Supplementary Figure 2 from Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer
Supplementary Figure 2 from Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer Open
PDF file, 41KB, Changes in weight during the study period for the mice randomized to the eight treatment groups described.
View article: Supplementary Figure 3 from Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer
Supplementary Figure 3 from Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer Open
PDF file, 327KB, Treatment of MIA-PaCa-2 cells with API-2 induces potent inhibition of Akt activation at 1 hour, regardless of the presence of PD0325901.
View article: Supplemental Data from A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis
Supplemental Data from A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis Open
Figure Legends